Marathi | HIndi

Epaper
Follow us:
Home > Topic > Drugs controller general of india
Drugs controller general of india

Drugs controller general of india

DCGI approves India's first CRISPR Covid-19 test developed by the Tata Group and CSIR-IGIB
National

DCGI approves India's first CRISPR Covid-19 test developed by the Tata Group and CSIR-IGIB

The Drug Controller General of India (DCGI), on Saturday gave approval for the commercial launch of India's first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) test, developed by the Tata Group and CSIR-IGIB (Institute of Genomics and Integrative Biology).

DCGI gives nod to Serum Institute to restart phase 2,3 trials for COVID-19 vaccine
National

DCGI gives nod to Serum Institute to restart phase 2,3 trials for COVID-19 vaccine

The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for COVID-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSMB), UK and DSMB India and requested permission to restart enrolment in the subject clinical trial of the vaccine being developed by AstraZeneca and Oxford University.

SII asked to submit approvals from DSMB India & UK to resume vax trial
Health

SII asked to submit approvals from DSMB India & UK to resume vax trial

New Delhi, Sep 12 The Drug Controller General of India (DCGI) has directed the Serum Institute of India ...

DCGI directs Serum Institute to suspend any new recruitment in phase 2, 3 COVID-19 vaccine clinical trials
National

DCGI directs Serum Institute to suspend any new recruitment in phase 2, 3 COVID-19 vaccine clinical trials

The Drugs Controller General of India (DCGI) Dr VG Somani on Friday ordered the pharma giant Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials for COVID-19 vaccine till further orders.

DCGI directs Serum Institute to suspend any new recruitment in phase 2, 3 COVID-19 vaccine clinical trials
National

DCGI directs Serum Institute to suspend any new recruitment in phase 2, 3 COVID-19 vaccine clinical trials

The Drugs Controller General of India (DCGI) Dr VG Somani on Friday ordered the pharma giant Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials for COVID-19 vaccine till further orders.

DCGI sends show cause notice to Serum Institute for not pausing trial of COVID-19 vaccine
National

DCGI sends show cause notice to Serum Institute for not pausing trial of COVID-19 vaccine

The Drugs Regulator General of India (DCGI) has issued a show-cause notice to pharma giant Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts about patient safety are cleared.

Dr Reddy's launches Redyx (Remdesivir) in India for COVID-19 treatment
Business

Dr Reddy's launches Redyx (Remdesivir) in India for COVID-19 treatment

Dr Reddy's Laboratories on Wednesday announced the launch of Remdesivir under the brand name Redyx for Indian markets.

Glenmark announces 400 mg 'FabiFlu' for Covid-19 treatment
Health

Glenmark announces 400 mg 'FabiFlu' for Covid-19 treatment

New Delhi, Aug 6 Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to ...

COVID-19: Health Ministry directs DCGI to ensure equitable distribution of 'investigational therapy' drugs nationwide
National

COVID-19: Health Ministry directs DCGI to ensure equitable distribution of 'investigational therapy' drugs nationwide

The Union Health and Family Welfare Ministry has directed the Drugs Controller General of India (DCGI) to ensure equitable distribution of drugs across the country included as part of "investigational therapies" in clinical management protocol for COVID-19.

COVID-19: Health ministry decides not to put Itolizumab in national treatment protocol
National

COVID-19: Health ministry decides not to put Itolizumab in national treatment protocol

Even as the Drugs Controller General of India (DCGI) has given permission to Itolizumab drug for restricted emergency use on moderate to severe COVID-19 patients, the Union Health Ministry has decided not to include the drug in the national treatment protocol for coronavirus patients.

Most Popular Stories

Corona
Patients5308014
Died85619
Corona
Patients30,940,524
Died960,224
Corona
Coronavirus Live updates! Around the world